Côte d'Ivoire vs Madagascar: Hepatitis B surface antigen (HBsAg) prevalence
Côte d'Ivoire
0.6%
in 2024
Madagascar
0.6%
in 2024
Côte d'Ivoire rank
51st
Madagascar rank
51st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Côte d'Ivoire
- Madagascar
How they compare
Côte d'Ivoire currently reports 0.6% against 0.6% in Madagascar, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Côte d'Ivoire ahead.
Côte d'Ivoire ranks 51st and Madagascar ranks 51st of 194 countries.
Côte d'Ivoire has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Côte d'Ivoire | Madagascar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.2% | 0.6% | 0.6% | Côte d'Ivoire |
| 2020s | 0.7% | 0.5% | 0.2% | Côte d'Ivoire |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Côte d'Ivoire or Madagascar?
- Côte d'Ivoire, at 0.6% against 0.6% in Madagascar as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Côte d'Ivoire and Madagascar?
- 0.0%, with Côte d'Ivoire ahead.
- How many years of comparable data are there for Côte d'Ivoire and Madagascar?
- 10 years are reported by both, from 2015 to 2024.
- How do Côte d'Ivoire and Madagascar rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Côte d'Ivoire ranks 51st and Madagascar ranks 51st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.